Overview

Therapy for Migraine Prevention in Children 6-11 Years of Age

Status:
Recruiting
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in pediatric patients 6 to 11 years old.
Phase:
Phase 4
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.